LEO 22811

DRUG3 trials

Sponsors

LEO Pharma

Conditions

HealthyPsoriasis Vulgaris

Phase 1

LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects

CompletedNCT00833872

LEO PharmaPsoriasis Vulgaris

Start: 2009-01-31End: 2009-11-30Updated: 2025-02-24

LEO 22811 - Single Dose Bioavailability Study of Tablet Versus Oral Solution in Healthy Subjects

CompletedNCT01211964

LEO PharmaHealthy

Start: 2010-09-30End: 2010-12-31Updated: 2025-02-24

Phase 2

A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris

CompletedNCT01116895

LEO PharmaPsoriasis Vulgaris

Start: 2010-05-31End: 2011-07-31Updated: 2025-03-07